TargetBeta
SMO
smoothened, frizzled class receptor · also FZD11, SMOH · G protein-coupled receptors, Class F frizzled
2 programs in company-led studies act on SMO, from 2 companies: 0 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
Conditions their studies are in
- Basal Cell Nevus Syndrome, 1 program
- Breast Neoplasms, 1 program
- Carcinoma, Basal Cell, 1 program
- Idiopathic Pulmonary Fibrosis, 1 program
- Laryngeal Diseases, 1 program
- Medulloblastoma, 1 program
- Neoplasm Metastasis, 1 program
- Neoplasms, 1 program
- Pancreatic Neoplasms, 1 program
- Small Cell Lung Carcinoma, 1 program
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.